Analyst Price Targets — VCYT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 8:55 am | David Westenberg | Piper Sandler | $66.00 | $56.62 | TheFly | Veracyte initiated with an Overweight at Piper Sandler |
| July 14, 2026 10:56 am | — | Canaccord Genuity | $60.00 | $57.48 | TheFly | Veracyte price target raised to $60 from $42 at Canaccord |
| July 9, 2026 10:59 am | — | Morgan Stanley | $47.00 | $56.12 | TheFly | Veracyte price target raised to $47 from $37 at Morgan Stanley |
| June 29, 2026 11:01 am | Subbu Nambi | Guggenheim | $65.00 | $60.49 | TheFly | Veracyte price target raised to $65 from $45 at Guggenheim |
| June 1, 2026 3:06 pm | Mike Matson | Needham | $57.00 | $48.38 | StreetInsider | Veracyte, Inc (VCYT) PT Raised to $57 at Needham |
| May 6, 2026 1:41 pm | — | UBS | $52.00 | $39.44 | TheFly | Veracyte price target raised to $52 from $48 at UBS |
| May 6, 2026 11:47 am | Kyle Mikson | Canaccord Genuity | $42.00 | $32.97 | TheFly | Veracyte price target raised to $42 from $40 at Canaccord |
| March 5, 2026 10:35 pm | Kallum Titchmarsh | Morgan Stanley | $37.00 | $34.68 | StreetInsider | Veracyte, Inc (VCYT) PT Lowered to $37 at Morgan Stanley |
| January 5, 2026 2:28 pm | Subbu Nambi | Guggenheim | $50.00 | $42.95 | TheFly | Veracyte price target raised to $50 from $45 at Guggenheim |
| December 1, 2025 9:36 pm | — | Morgan Stanley | $48.00 | $46.39 | TheFly | Veracyte assumed with an Underweight at Morgan Stanley |
Latest News for VCYT
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same…
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transaction value of ~$1.09 million at an average price around $45.40 per share. This transaction reduced direct holdings by 34.57%, leaving 45,434 shares directly owned post-sale.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCYT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.